… burn wound model, applied XF-73 topically to MRSA-infected burn … highlighted the potential of XF-73 to significantly reduce the … provide clear evidence that XF-73 can significantly reduce the … the continued development of our XF-73 dermal product.” At 1408 …

… work being carried out on XF-73 Dermal, which has delivered a … on the potential toxicity of XF-73 Dermal applied to broken skin … the preclinical safety study in XF-73 Dermal and I am delighted … these results, we can move XF-73 Dermal into the clinic with …

… on its leading antibacterial drug, XF-73, showed its effectiveness against all …

… proprietary, synthetic dicationic porphyrin drug, XF-73 (exeporfinium chloride). Preliminary in vitro … in vitro activity of XF-73, indicating that XF-73 has excellent bactericidal … following exposure to XF-73. TEM images show that XF-73 initially disrupts …

… partner for its lead asset, XF-73, a nasal gel that decolonizes …

… clinical data regarding its XF-73 candidate in the Infection … its primary endpoint, with XF-73 demonstrating a 99.5% lowering … infection control.” He added: “XF-73 nasal gel is a potential … Ohio State University, added: “XF-73 provides a rapidly effective and …

… ;s new nasal gel, called XF-73, in the US journal …

… News! » Destiny Pharma’s XF-73 dermal infection project advances to … started for Destiny Pharma’s XF-73 dermal formulation. The company … future clinical development of XF-73 Dermal in serious wound … progress of our novel XF-73 Dermal infection program, which …

… .S. registration pathway for its XF-73 nasal gel, which is being …